In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect Corp (DRRX), with a price target of $3.50. The company’s shares closed yesterday at $0.86.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 11.6% and a 41.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
Durect Corp has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See today’s analyst top recommended stocks >>
Based on Durect Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.13 million. In comparison, last year the company had a GAAP net loss of $8.3 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel.
